These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 22795503)

  • 1. Complete surgical resection of lung tumor decreases exhalation of mutated KRAS oncogene.
    Kordiak J; Szemraj J; Hamara K; Bialasiewicz P; Nowak D
    Respir Med; 2012 Sep; 106(9):1293-300. PubMed ID: 22795503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate.
    Kordiak J; Szemraj J; Grabska-Kobylecka I; Bialasiewicz P; Braun M; Kordek R; Nowak D
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):241-251. PubMed ID: 30368666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3p microsatellite signature in exhaled breath condensate and tumor tissue of patients with lung cancer.
    Carpagnano GE; Foschino-Barbaro MP; Spanevello A; Resta O; Carpagnano F; Mulé G; Pinto R; Tommasi S; Paradiso A
    Am J Respir Crit Care Med; 2008 Feb; 177(3):337-41. PubMed ID: 17962633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
    Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
    Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer.
    Carpagnano GE; Foschino-Barbaro MP; Mulé G; Resta O; Tommasi S; Mangia A; Carpagnano F; Stea G; Susca A; Di Gioia G; De Lena M; Paradiso A
    Am J Respir Crit Care Med; 2005 Sep; 172(6):738-44. PubMed ID: 15947287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer.
    Wang S; An T; Wang J; Zhao J; Wang Z; Zhuo M; Bai H; Yang L; Zhang Y; Wang X; Duan J; Wang Y; Guo Q; Wu M
    Clin Cancer Res; 2010 Feb; 16(4):1324-30. PubMed ID: 20145159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
    Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
    Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer.
    Uchiyama M; Usami N; Kondo M; Mori S; Ito M; Ito G; Yoshioka H; Imaizumi M; Ueda Y; Takahashi M; Minna JD; Shimokata K; Sekido Y
    Int J Cancer; 2003 Dec; 107(6):962-9. PubMed ID: 14601056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low mutational rate of K-ras codon 12 in singular bronchoscopy specimens in suspected lung cancer.
    Spasova I; Novotna H; Vachtenheim J; Bartosova H; Patek J; Hoserova V; Zatloukal P; Kinkor Z
    Neoplasma; 2005; 52(3):255-9. PubMed ID: 15875089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of P16 in exhaled breath condensate for diagnosis of non-small cell lung cancer.
    Xiao P; Chen JR; Zhou F; Lu CX; Yang Q; Tao GH; Tao YJ; Chen JL
    Lung Cancer; 2014 Jan; 83(1):56-60. PubMed ID: 24268095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory markers in exhaled breath condensate following lung resection for bronchial carcinoma.
    Jungraithmayr W; Frings C; Zissel G; Prasse A; Passlick B; Stoelben E
    Respirology; 2008 Nov; 13(7):1022-7. PubMed ID: 18764914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of exhaled microsatellite alterations at 3p in NSCLC patients.
    Carpagnano GE; Spanevello A; Carpagnano F; Palladino GP; Prato R; Martinelli D; Digioia G; Foschino-Barbaro MP
    Lung Cancer; 2009 Jun; 64(3):334-40. PubMed ID: 18995925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of exhaled sICAM1, sVCAM1, and sE-selectin in patients with non-small cell lung cancer.
    Zhou F; Chen J; Tao G; Zhu M; Xie W; Cao X
    Respir Med; 2014 Nov; 108(11):1670-6. PubMed ID: 25179787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
    Youssef O; Knuuttila A; Piirilä P; Böhling T; Sarhadi V; Knuutila S
    Anticancer Res; 2018 Oct; 38(10):5627-5634. PubMed ID: 30275180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of specific KRAS mutations in lung adenocarcinomas.
    Siegfried JM; Gillespie AT; Mera R; Casey TJ; Keohavong P; Testa JR; Hunt JD
    Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):841-7. PubMed ID: 9332768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases.
    Cortot AB; Italiano A; Burel-Vandenbos F; Martel-Planche G; Hainaut P
    Cancer; 2010 Jun; 116(11):2682-7. PubMed ID: 20336783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.
    Wu CC; Hsu HY; Liu HP; Chang JW; Chen YT; Hsieh WY; Hsieh JJ; Hsieh MS; Chen YR; Huang SF
    Cancer; 2008 Dec; 113(11):3199-208. PubMed ID: 18932251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.